Keep Informed on Legal and Compliance Developments Affecting Diagnostic Labs
Best practices and expert insight to help lab professionals comply with regulations and identify strategic trends in business and technology
Already a Subscriber? Log in Here
Lab Industry Advisor Subscription
Struggling with Staying Informed? In the fast-paced world of diagnostic medicine, staying updated with the latest legal, compliance, regulatory, and industry insights is crucial. Yet, finding reliable and comprehensive information can be overwhelming and time-consuming.
Lab Industry Advisor to the Rescue! Lab Industry Advisor provides comprehensive, up-to-date insights and analyses tailored to your needs. With expert commentary and actionable advice, you’ll stay ahead of the curve. No more sifting through endless sources—everything you need is right here!
Start your free trial today and see how Lab Industry Advisor can transform your approach. Get instant access to invaluable resources designed to keep you informed and competitive. Explore detailed reports, in-depth articles, and exclusive industry insights that help you make better decisions faster. Choose from three subscription levels tailored to fit your needs: Essential, Premium, and Elite.
![Essential](https://www.g2intelligence.com/wp-content/uploads/2023/11/Essential.png)
![62934_G2_Subscription Website Images_JL V1](https://www.g2intelligence.com/wp-content/uploads/2023/11/62934_G2_Subscription-Website-Images_JL-V1.png)
![Special-Report](https://www.g2intelligence.com/wp-content/uploads/2023/11/Special-Report.png)
![62934_G2_Subscription Website Images_JL V12](https://www.g2intelligence.com/wp-content/uploads/2023/11/62934_G2_Subscription-Website-Images_JL-V12.png)
![Special-Analysis](https://www.g2intelligence.com/wp-content/uploads/2023/11/Special-Analysis.png)
![Elite](https://www.g2intelligence.com/wp-content/uploads/2023/11/Elite.png)
Additional Business Intelligence Offerings
Lab Industry Advisor Subscriptions Include
![paper_magnifing_glass_512](https://www.g2intelligence.com/wp-content/uploads/2023/11/paper_magnifing_glass_512.png)
Analysis and insight on key compliance, legal, and business developments affecting laboratories
- Updates on changes to regulations
- Healthcare-related laws
- FDA approvals
- Business deals in the diagnostics space, and more
Latest Articles
New FDA LDTs Guidance Offers Useful Summary, But Questions Remain
Recently released document for small labs offers a more digestible version of the final rule requirements but still lacks key details
At ACLA Meeting, Relief and Resolve in the Wake of Major Policy Changes
By Stephanie Murg, Managing Director, G2 Intelligence What a difference a year makes. That was the prevailing sentiment at the opening sessions of the 20th annual meeting of the American Clinical Laboratory Association (ACLA), which runs through today at the Grand...
Health Care Entities Getting Hit with Costs for Information Security Incidents
By Kelly A. Briganti, Editorial Director, G2 Intelligence As an Oregon health care insurer just experienced, if your lab suffers an information security breach, even due to a lost laptop or flash drive, the Health Insurance Portability and Accountability Act...
Aetna Sues Troubled Laboratory for “Tens of Millions” for Fraud
By Christopher P. Young, Editor, G2 Compliance Advisor Aetna alleges Health Diagnostic Laboratory, Inc. (HDL), and Bluewave Healthcare Consultants, Inc. used kickbacks and inducements to redirect referrals for laboratory testing to HDL, an out-of-network...
Adaptive Biotechnologies, MD Anderson Create Assay to Detect Hodgkin’s Disease
By Ron Shinkman, Editor, Laboratory Industry Report Adaptive Biotechnologies has said it has developed an assay to help detect Hodgkin's disease through a blood draw. The Seattle-based Adaptive worked with the University of Texas MD Anderson Cancer Center in...
Large Survey Finds Return of Research Sequencing Results Desired
By Lori Solomon, Editor, Diagnostic Testing & Emerging Technologies Although there is general interest in receiving genomic results from sequencing study participation, most people do not expect researchers to go out of their way to screen for incidental findings...